Liraglutide, aka Saxenda®, a drug commonly used for obesity, has been found to restore impaired associative learning in individuals with obesity. This discovery was made by Ruth Hanssen and published in the journal "Nature Metabolism" in August 2023.1 The research highlights the potential of liraglutide to enhance cognitive functions, specifically in the realm of learning.
Share this post